Verinurad + Placebo + Allopurinol
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Healthy Volunteers (Intended Indication: Chronic Kidney Disease)
Conditions
Healthy Volunteers (Intended Indication: Chronic Kidney Disease)
Trial Timeline
Mar 3, 2020 → Aug 21, 2020
NCT ID
NCT04256629About Verinurad + Placebo + Allopurinol
Verinurad + Placebo + Allopurinol is a phase 1 stage product being developed by AstraZeneca for Healthy Volunteers (Intended Indication: Chronic Kidney Disease). The current trial status is completed. This product is registered under clinical trial identifier NCT04256629. Target conditions include Healthy Volunteers (Intended Indication: Chronic Kidney Disease).
What happened to similar drugs?
20 of 20 similar drugs in Healthy Volunteers (Intended Indication: Chronic Kidney Disease) were approved
Approved (20) Terminated (1) Active (0)
✅Listerine Experimental Mouthwash + Colgate Cavity Protection Toothpaste + Listerine Total Care ZeroJohnson & JohnsonApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04256629 | Phase 1 | Completed |
Competing Products
20 competing products in Healthy Volunteers (Intended Indication: Chronic Kidney Disease)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0837 | AstraZeneca | Phase 1 | 29 |
| Valsartan | Novartis | Phase 1 | 29 |
| CSL112 + Placebo | CSL | Phase 1 | 29 |
| UT-15C | United Therapeutics | Phase 1 | 26 |
| VNA-318 + Placebo | Biotrial | Phase 1 | 19 |
| Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + Placebo | Trevena | Phase 1 | 19 |
| TRV130 + Moxifloxacin + Placebo | Trevena | Phase 1 | 19 |
| Radiolabeled TRV130 | Trevena | Phase 1 | 19 |
| TRV130A + Dextrose in Water | Trevena | Phase 1 | 19 |
| TRV734 | Trevena | Phase 1 | 19 |
| ALT02 + EU-licensed Herceptin + US-licensed Herceptin | Alteogen | Phase 1 | 29 |
| ENZ215 + EU Sourced Prolia + US Sourced Prolia | Alkem Laboratories | Phase 1 | 29 |
| KPL-404 | Kiniksa Pharmaceuticals | Phase 1 | 23 |
| MORF-057 + Placebo for MORF-057 | Eli Lilly | Phase 1 | 29 |
| Propranolol + Pseudoephedrine | Eli Lilly | Pre-clinical | 26 |
| LY2157299 | Eli Lilly | Phase 1 | 29 |
| Lasmiditan + Placebo | Eli Lilly | Phase 1 | 29 |
| LY3015014 + Placebo | Eli Lilly | Phase 1 | 29 |
| LOXO-783 | Eli Lilly | Phase 1 | 29 |
| LY2541546 - IV + LY2541546 - SC + Placebo | Eli Lilly | Phase 1 | 29 |